The Evolution of Chronic Kidney Disease: Defining a Model for Care

World Congress of Nephrology (ASN/ISN), San Francisco, CA, October, 2001
Access to this program is free but HDCN free zone registration is required.
A Welcome and Introductory Remarks
Ajay Singh, M.B / Paul Kimmel, M.D.
Prevalence and Current Treatment of Chronic Kidney Disease: The Background
William McClellan, M.D.
Optimizing Anemia Management in Patients with CKD
Robert Provenzano, M.D.
Correcting the Mild Anemia of Severe, Resistant Congestive Heart Failure (CHF): The Effect on Cardiorenal Function
Donald Silverberg, M.D.
Update on Renal Disease Management
John Dickmeyer, M.D.
Questions and Answers
Speakers and moderators

After participating in this activity, participants should be able to:

Discuss the prevalence of chronic kidney disease (CKD) in the US population and suboptimal treatment of anemia;
Summarize the advances made in defining the stages of CKD and describe current guidelines for anemia correction;
Describe the effects of the correction of anemia on cardiorenal function in patients with congestive heart failure (CHF): and
Summarize knowledge about treatment plans and models of care that are directed at improving CKD treatment and limiting progression of disease.

John Dickmeyer, M.D.
Senior Vice President
RMS Disease Management, Inc.
Lafayette, CA, USA

Paul Kimmel, M.D.
Professor of Medicine
George Washington University
Medical Center
Washington, DC, USA

William McClellan, M.D., MPH
Clinical Professor of Medicine
Emory University
School of Medicine
Atlanta, GA, USA

Robert Provenzano, M.D., FACP
Chair, Department of Nephrology
St. John Hospital and Medical Center
Detroit, MI, USA

Donald Silverberg, M.D.
Department of Nephrology
Tel Aviv Medical Center
Department of Nephrology
Tel Aviv, Israel

Ajay Singh, M.B., M.R.C.P.
Associate Professor of Medicine
Harvard Medical School
Boston, MA, USA

CME

CEU

Post-test and evaluation form are at this link, but you must listen to all talks from this symposium prior to completing the test.
CME: The University of Minnesota is accredited by the Accreditation Council for Continuing Medical Education (AACME) to sponsor continuing medical education for physicians.
The University of Minnesota designates this educational activity for up to 1.5 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit actually spent in the educational activity.

CEU: These talks are also designated to provide 1.5 hours of CEU Nursing Education credits, sponsored by the Renal Education Association. The Renal Education Association is accredited by the State of California Board of Nursing to provide continuing education for nurses (Provider number: CEP 13092).

Posting date: January 15, 2002.
Review date: January 15, 2003

INSTRUCTIONS FOR CREDIT :
Participation in this self-study activity should be completed in approximately two (1.5) hours. There are no fees for participating and receiving CME or CEU credit for this activity. To successfully complete this activity and receive credit, participants must follow these steps during the period January 15, 2002 through January 15, 2003.
1. Register for continuing education credit by completing the registration process.
2. Read the goals and learning objectives.
3. Read the article text and tables, and review figures.
4. Read, complete, and submit answers to the post test questions and evaluation questions. You must receive a test score of at least 75% and respond to all evaluation questions to receive your online CME or CEU certificate.

TARGET AUDIENCE :
The primary target audience is physicians involved in the care of renal patients (CME), and nephrology nurses, dialysis technicians and pharmacists (CEU).

FACULTY DISCLOSURE STATEMENTS :
All faculty participating in continuing medical education programs are expected to disclose to the program audience any real or apparent conflict of interest related to the subject under discussion. The faculty disclosure information is as follows:
Dickmeyer, John: Stocks (directly purchases): RMS Disease Management
Kimmel, Paul: No potential conflicts of interest.
McClellan: Other financial or material support: Ortho Biotech Products, L.P.: Early Renal Insufficiency Advisory Group
Provenzano, Robert: Consultant, Ortho Biotech; Advisory Board, Amgen
Singh, Ajay: Consultant to: Ortho Biotech, Amgen, Pfizer, Merck, Pharmacia, Genzyme; Research Support: Amgen, Ortho Biotech
Silverberg, Donald: Consultantships: Amgen, Johnson and Johnson

DISCLOSURE OF UNLABELED USE:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The University of Minnesota, ASN, HDCN and the Renal Education Association do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

This educational activity is supported by an educational grant from Ortho Biotech Products, L.P.
This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies and with CE policies of the State of California Board of Registered Nursing.
This educational activity is based on an ASN/ISN evening symposium which was
planned by the World Congress of Nephrology program committee.
BACK TO
TOPIC INDEX :